ApoE and Aβ in Alzheimer's disease: Accidental encounters or partners?

Neuron

Volumn 81, Issue 4, 2014, Pages 740-754

  Kanekiyo, Takahisa ^a   Xu, Huaxi ^b   Bu, Guojun ^a,b  

^a MAYO GRADUATE SCHOOL   (United States)

^b XIAMEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[12-28P]; APOLIPOPROTEIN E; APOLIPOPROTEIN E RECEPTOR; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; AQUAPORIN 4; BEXAROTENE; CENTRAL NERVOUS SYSTEM AGENTS; CHOLESTEROL; INSULINASE; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; LOW DENSITY LIPOPROTEIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; MEMBRANE METALLOENDOPEPTIDASE; MESSENGER RNA; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PROTEOHEPARAN SULFATE; RETINOID X RECEPTOR; RETINOID X RECEPTOR AGONIST; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN RECEPTOR; ISOPROTEIN;

ALZHEIMER DISEASE; AMNESIA; ASTROCYTE; BINDING AFFINITY; BLOOD BRAIN BARRIER; CELL ACTIVATION; CELL INTERACTION; CELL SURFACE; CELLULAR SECRETION; CHOLESTEROL TRANSPORT; CLEARANCE; COGNITION; DRUG ACTIVITY; ENDOCYTOSIS; ENDOSOME; GENETIC RISK; HUMAN; IMMUNIZATION; INTERNALIZATION; INTERSTITIAL FLUID; LYSOSOME; MACROPHAGE; MICROGLIA; NEUROTOXICITY; NONHUMAN; OLIGOMERIZATION; PATHOPHYSIOLOGY; PINOCYTOSIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN STRUCTURE; PROTEIN TARGETING; PROTEIN TRANSPORT; REVIEW; SIALYLATION; TISSUE DISTRIBUTION; AMYLOIDOSIS; APOLIPOPROTEIN E GENE; CELL MIGRATION; COMPLEX FORMATION; HIGH RISK PATIENT; MOLECULARLY TARGETED THERAPY; NEUROPATHOLOGY; PROTEIN FUNCTION; STRUCTURE ANALYSIS;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOLIPOPROTEINS E; BRAIN; HUMANS; NEURONS; RISK FACTORS;

EID: 84896726518     PISSN: 08966273     EISSN: 10974199     Source Type: Journal    
DOI: 10.1016/j.neuron.2014.01.045     Document Type: Review

References (163)

1. Aguzzi A., Barres B.A., Bennett M.L. Microglia: scapegoat, saboteur, or something else?. Science 2013, 339:156-161.
2. Baitsch D., Bock H.H., Engel T., Telgmann R., Müller-Tidow C., Varga G., Bot M., Herz J., Robenek H., von Eckardstein A., Nofer J.R. Apolipoprotein E induces antiinflammatory phenotype in macrophages. Arterioscler. Thromb. Vasc. Biol. 2011, 31:1160-1168.
3. Bales K.R., Verina T., Dodel R.C., Du Y., Altstiel L., Bender M., Hyslop P., Johnstone E.M., Little S.P., Cummins D.J., et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat. Genet. 1997, 17:263-264.
4. Bales K.R., Liu F., Wu S., Lin S., Koger D., DeLong C., Hansen J.C., Sullivan P.M., Paul S.M. Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J.Neurosci. 2009, 29:6771-6779.
5. Bamberger M.E., Harris M.E., McDonald D.R., Husemann J., Landreth G.E. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J.Neurosci. 2003, 23:2665-2674.
6. Basak J.M., Verghese P.B., Yoon H., Kim J., Holtzman D.M. Low-density lipoprotein receptor represents an apolipoprotein E-independent pathway of Aβ uptake and degradation by astrocytes. J.Biol. Chem. 2012, 287:13959-13971.
7. Bateman R.J., Munsell L.Y., Morris J.C., Swarm R., Yarasheski K.E., Holtzman D.M. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid invivo. Nat. Med. 2006, 12:856-861.
8. Beisiegel U., Weber W., Ihrke G., Herz J., Stanley K.K. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature 1989, 341:162-164.
9. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., Zlokovic B.V. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. J.Cereb. Blood Flow Metab. 2007, 27:909-918.
10. Bell R.D., Deane R., Chow N., Long X., Sagare A., Singh I., Streb J.W., Guo H., Rubio A., Van Nostrand W., et al. SRF and myocardin regulate LRP-mediated amyloid-beta clearance in brain vascular cells. Nat. Cell Biol. 2009, 11:143-153.
11. Bell R.D., Winkler E.A., Singh I., Sagare A.P., Deane R., Wu Z., Holtzman D.M., Betsholtz C., Armulik A., Sallstrom J., et al. Apolipoprotein E controls cerebrovascular integrity via cyclophilin A. Nature 2012, 485:512-516.
12. Bergamaschini L., Rossi E., Storini C., Pizzimenti S., Distaso M., Perego C., De Luigi A., Vergani C., De Simoni M.G. Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J.Neurosci. 2004, 24:4181-4186.
13. Bien-Ly N., Gillespie A.K., Walker D., Yoon S.Y., Huang Y. Reducing human apolipoprotein E levels attenuates age-dependent Aβ accumulation in mutant human amyloid precursor protein transgenic mice. J.Neurosci. 2012, 32:4803-4811.
14. Brunden K.R., Richter-Cook N.J., Chaturvedi N., Frederickson R.C. pH-dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans. J.Neurochem. 1993, 61:2147-2154.
15. Bu G. Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy. Nat. Rev. Neurosci. 2009, 10:333-344.
16. Cao D., Fukuchi K., Wan H., Kim H., Li L. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol. Aging 2006, 27:1632-1643.
17. Castano E.M., Prelli F., Wisniewski T., Golabek A., Kumar R.A., Soto C., Frangione B. Fibrillogenesis in Alzheimer's disease of amyloid beta peptides and apolipoprotein E. Biochem. J. 1995, 306:599-604.
18. Castellano J.M., Kim J., Stewart F.R., Jiang H., DeMattos R.B., Patterson B.W., Fagan A.M., Morris J.C., Mawuenyega K.G., Cruchaga C., et al. Human apoE isoforms differentially regulate brain amyloid-β peptide clearance. Sci. Transl. Med. 2011, 3:89ra57.
19. Castellano J.M., Deane R., Gottesdiener A.J., Verghese P.B., Stewart F.R., West T., Paoletti A.C., Kasper T.R., DeMattos R.B., Zlokovic B.V., Holtzman D.M. Low-density lipoprotein receptor overexpression enhances the rate of brain-to-blood Aβ clearance in a mouse model of β-amyloidosis. Proc. Natl. Acad. Sci. USA 2012, 109:15502-15507.
20. Cerf E., Gustot A., Goormaghtigh E., Ruysschaert J.M., Raussens V. High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease. FASEB J. 2011, 25:1585-1595.
21. Chan W., Fornwald J., Brawner M., Wetzel R. Native complex formation between apolipoprotein E isoforms and the Alzheimer's disease peptide A beta. Biochemistry 1996, 35:7123-7130.
22. Chartier-Harlin M.C., Parfitt M., Legrain S., Pérez-Tur J., Brousseau T., Evans A., Berr C., Vidal O., Roques P., Gourlet V., et al. Apolipoprotein E, epsilon 4 allele as a major risk factor for sporadic early and late-onset forms of Alzheimer's disease: analysis of the 19q13.2 chromosomal region. Hum. Mol. Genet. 1994, 3:569-574.
23. Chen J., Li Q., Wang J. Topology of human apolipoprotein E3uniquely regulates its diverse biological functions. Proc. Natl. Acad. Sci. USA 2011, 108:14813-14818.
24. Chen H.K., Liu Z., Meyer-Franke A., Brodbeck J., Miranda R.D., McGuire J.G., Pleiss M.A., Ji Z.S., Balestra M.E., Walker D.W., et al. Small molecule structure correctors abolish detrimental effects of apolipoprotein E4 in cultured neurons. J.Biol. Chem. 2012, 287:5253-5266.
25. Corder E.H., Saunders A.M., Strittmatter W.J., Schmechel D.E., Gaskell P.C., Small G.W., Roses A.D., Haines J.L., Pericak-Vance M.A. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993, 261:921-923.
26. Cramer P.E., Cirrito J.R., Wesson D.W., Lee C.Y., Karlo J.C., Zinn A.E., Casali B.T., Restivo J.L., Goebel W.D., James M.J., et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 2012, 335:1503-1506.
27. Cruchaga C., Kauwe J.S., Nowotny P., Bales K., Pickering E.H., Mayo K., Bertelsen S., Hinrichs A., Fagan A.M., Holtzman D.M., et al. Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease. Hum. Mol. Genet. 2012, 21:4558-4571. Alzheimer's Disease Neuroimaging Initiative.
28. Cudaback E., Li X., Montine K.S., Montine T.J., Keene C.D. Apolipoprotein E isoform-dependent microglia migration. FASEB J. 2011, 25:2082-2091.
29. Davignon J., Gregg R.E., Sing C.F. Apolipoprotein E polymorphism and atherosclerosis. Arteriosclerosis 1988, 8:1-21.
30. de Boer A.G., Gaillard P.J. Drug targeting to the brain. Annu. Rev. Pharmacol. Toxicol. 2007, 47:323-355.
31. de la Torre J.C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002, 33:1152-1162.
32. Deane R., Wu Z., Sagare A., Davis J., Du Yan S., Hamm K., Xu F., Parisi M., LaRue B., Hu H.W., et al. LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 2004, 43:333-344.
33. Deane R., Sagare A., Hamm K., Parisi M., Lane S., Finn M.B., Holtzman D.M., Zlokovic B.V. apoE isoform-specific disruption of amyloid beta peptide clearance from mouse brain. J.Clin. Invest. 2008, 118:4002-4013.
34. DeMattos R.B., Cirrito J.R., Parsadanian M., May P.C., O'Dell M.A., Taylor J.W., Harmony J.A., Aronow B.J., Bales K.R., Paul S.M., Holtzman D.M. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism invivo. Neuron 2004, 41:193-202.
35. Dong L.M., Wilson C., Wardell M.R., Simmons T., Mahley R.W., Weisgraber K.H., Agard D.A. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J.Biol. Chem. 1994, 269:22358-22365.
36. Elshourbagy N.A., Liao W.S., Mahley R.W., Taylor J.M. Apolipoprotein E mRNA is abundant in the brain and adrenals, as well as in the liver, and is present in other peripheral tissues of rats and marmosets. Proc. Natl. Acad. Sci. USA 1985, 82:203-207.
37. Fagan A.M., Mintun M.A., Mach R.H., Lee S.Y., Dence C.S., Shah A.R., LaRossa G.N., Spinner M.L., Klunk W.E., Mathis C.A., et al. Inverse relation between invivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann. Neurol. 2006, 59:512-519.
38. Fan Q.W., Iosbe I., Asou H., Yanagisawa K., Michikawa M. Expression and regulation of apolipoprotein E receptors in the cells of the central nervous system in culture: A review. J.Am. Aging Assoc. 2001, 24:1-10.
39. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. JAMA 1997, 278:1349-1356. APOE and Alzheimer Disease Meta Analysis Consortium.
40. Farris W., Mansourian S., Chang Y., Lindsley L., Eckman E.A., Frosch M.P., Eckman C.B., Tanzi R.E., Selkoe D.J., Guenette S. Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain invivo. Proc. Natl. Acad. Sci. USA 2003, 100:4162-4167.
41. Farris W., Schütz S.G., Cirrito J.R., Shankar G.M., Sun X., George A., Leissring M.A., Walsh D.M., Qiu W.Q., Holtzman D.M., Selkoe D.J. Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am. J. Pathol. 2007, 171:241-251.
42. Fitz N.F., Cronican A.A., Saleem M., Fauq A.H., Chapman R., Lefterov I., Koldamova R. Abca1 deficiency affects Alzheimer's disease-like phenotype in human ApoE4 but not in ApoE3-targeted replacement mice. J.Neurosci. 2012, 32:13125-13136.
43. Fryer J.D., Demattos R.B., McCormick L.M., O'Dell M.A., Spinner M.L., Bales K.R., Paul S.M., Sullivan P.M., Parsadanian M., Bu G., Holtzman D.M. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J.Biol. Chem. 2005, 280:25754-25759.
44. Fryer J.D., Simmons K., Parsadanian M., Bales K.R., Paul S.M., Sullivan P.M., Holtzman D.M. Human apolipoprotein E4 alters the amyloid-beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J.Neurosci. 2005, 25:2803-2810.
45. Futamura M., Dhanasekaran P., Handa T., Phillips M.C., Lund-Katz S., Saito H. Two-step mechanism of binding of apolipoprotein E to heparin: implications for the kinetics of apolipoprotein E-heparan sulfate proteoglycan complex formation on cell surfaces. J.Biol. Chem. 2005, 280:5414-5422.
46. Garai K., Baban B., Frieden C. Self-association and stability of the ApoE isoforms at low pH: implications for ApoE-lipid interactions. Biochemistry 2011, 50:6356-6364.
47. Golabek A.A., Soto C., Vogel T., Wisniewski T. The interaction between apolipoprotein E and Alzheimer's amyloid beta-peptide is dependent on beta-peptide conformation. J.Biol. Chem. 1996, 271:10602-10606.
48. Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., et al. TREM2 variants in Alzheimer's disease. N.Engl. J. Med. 2013, 368:117-127. Alzheimer Genetic Analysis Group.
49. Guo J.L., Covell D.J., Daniels J.P., Iba M., Stieber A., Zhang B., Riddle D.M., Kwong L.K., Xu Y., Trojanowski J.Q., Lee V.M. Distinct α-synuclein strains differentially promote tau inclusions in neurons. Cell 2013, 154:103-117.
50. Gylys K.H., Fein J.A., Tan A.M., Cole G.M. Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. J.Neurochem. 2003, 84:1442-1451.
51. Hardy J., Selkoe D.J. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002, 297:353-356.
52. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet. 2009, 41:1088-1093.
53. Harper J.D., Lansbury P.T. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu. Rev. Biochem. 1997, 66:385-407.
54. Hashimoto T., Serrano-Pozo A., Hori Y., Adams K.W., Takeda S., Banerji A.O., Mitani A., Joyner D., Thyssen D.H., Bacskai B.J., et al. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. J.Neurosci. 2012, 32:15181-15192.
55. Hatters D.M., Budamagunta M.S., Voss J.C., Weisgraber K.H. Modulation of apolipoprotein E structure by domain interaction: differences in lipid-bound and lipid-free forms. J.Biol. Chem. 2005, 280:34288-34295.
56. Hatters D.M., Peters-Libeu C.A., Weisgraber K.H. Apolipoprotein E structure: insights into function. Trends Biochem. Sci. 2006, 31:445-454.
57. Hatters D.M., Zhong N., Rutenber E., Weisgraber K.H. Amino-terminal domain stability mediates apolipoprotein E aggregation into neurotoxic fibrils. J.Mol. Biol. 2006, 361:932-944.
58. Herz J., Strickland D.K. LRP: a multifunctional scavenger and signaling receptor. J.Clin. Invest. 2001, 108:779-784.
59. Hesse C., Larsson H., Fredman P., Minthon L., Andreasen N., Davidsson P., Blennow K. Measurement of apolipoprotein E (apoE) in cerebrospinal fluid. Neurochem. Res. 2000, 25:511-517.
60. Hollingworth P., Harold D., Sims R., Gerrish A., Lambert J.C., Carrasquillo M.M., Abraham R., Hamshere M.L., Pahwa J.S., Moskvina V., et al. Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat. Genet. 2011, 43:429-435. Alzheimer's Disease Neuroimaging Initiative, CHARGE consortiumCHARGE consortium, EADI1 consortiumEADI1 consortium.
61. Holmes B.B., DeVos S.L., Kfoury N., Li M., Jacks R., Yanamandra K., Ouidja M.O., Brodsky F.M., Marasa J., Bagchi D.P., et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds. Proc. Natl. Acad. Sci. USA 2013, 110:E3138-E3147.
62. Holtzman D.M., Bales K.R., Wu S., Bhat P., Parsadanian M., Fagan A.M., Chang L.K., Sun Y., Paul S.M. Expression of human apolipoprotein E reduces amyloid-beta deposition in a mouse model of Alzheimer's disease. J.Clin. Invest. 1999, 103:R15-R21.
63. Houlden H., Crook R., Backhovens H., Prihar G., Baker M., Hutton M., Rossor M., Martin J.J., Van Broeckhoven C., Hardy J. ApoE genotype is a risk factor in nonpresenilin early-onset Alzheimer's disease families. Am. J. Med. Genet. 1998, 81:117-121.
64. Hu X., Crick S.L., Bu G., Frieden C., Pappu R.V., Lee J.M. Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide. Proc. Natl. Acad. Sci. USA 2009, 106:20324-20329.
65. Huang Y., Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012, 148:1204-1222.
66. Iliff J.J., Wang M., Liao Y., Plogg B.A., Peng W., Gundersen G.A., Benveniste H., Vates G.E., Deane R., Goldman S.A., et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid beta. Sci. Transl. Med. 2012, 4:147ra111.
67. Innerarity T.L., Mahley R.W. Enhanced binding by cultured human fibroblasts of apo-E-containing lipoproteins as compared with low density lipoproteins. Biochemistry 1978, 17:1440-1447.
68. Innerarity T.L., Pitas R.E., Mahley R.W. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. J.Biol. Chem. 1979, 254:4186-4190.
69. Irizarry M.C., Rebeck G.W., Cheung B., Bales K., Paul S.M., Holzman D., Hyman B.T. Modulation of A beta deposition in APP transgenic mice by an apolipoprotein E null background. Ann. N Y Acad. Sci. 2000, 920:171-178.
70. Ito S., Matsumiya K., Ohtsuki S., Kamiie J., Terasaki T. Contributions of degradation and brain-to-blood elimination across the blood-brain barrier to cerebral clearance of human amyloid-beta peptide(1-40) in mouse brain. J.Cereb. Blood Flow Metab. 2013, 33. 1770-1177.
71. Iwata N., Tsubuki S., Takaki Y., Watanabe K., Sekiguchi M., Hosoki E., Kawashima-Morishima M., Lee H.J., Hama E., Sekine-Aizawa Y., Saido T.C. Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat. Med. 2000, 6:143-150.
72. Ji Z.S., Brecht W.J., Miranda R.D., Hussain M.M., Innerarity T.L., Mahley R.W. Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J.Biol. Chem. 1993, 268:10160-10167.
73. Jiang Q., Lee C.Y., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Willson T.M., Collins J.L., et al. ApoE promotes the proteolytic degradation of Abeta. Neuron 2008, 58:681-693.
74. Kanekiyo T., Zhang J., Liu Q., Liu C.C., Zhang L., Bu G. Heparan sulphate proteoglycan and the low-density lipoprotein receptor-related protein 1 constitute major pathways for neuronal amyloid-beta uptake. J.Neurosci. 2011, 31:1644-1651.
75. Kanekiyo T., Liu C.C., Shinohara M., Li J., Bu G. LRP1 in brain vascular smooth muscle cells mediates local clearance of Alzheimer's amyloid-β. J.Neurosci. 2012, 32:16458-16465.
76. Kanekiyo T., Cirrito J.R., Liu C.C., Shinohara M., Li J., Schuler D.R., Shinohara M., Holtzman D.M., Bu G. Neuronal clearance of amyloid-β by endocytic receptor LRP1. J.Neurosci. 2013, 33:19276-19283.
77. Kim D.H., Iijima H., Goto K., Sakai J., Ishii H., Kim H.J., Suzuki H., Kondo H., Saeki S., Yamamoto T. Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. J.Biol. Chem. 1996, 271:8373-8380.
78. Kim J., Castellano J.M., Jiang H., Basak J.M., Parsadanian M., Pham V., Mason S.M., Paul S.M., Holtzman D.M. Overexpression of low-density lipoprotein receptor in the brain markedly inhibits amyloid deposition and increases extracellular A beta clearance. Neuron 2009, 64:632-644.
79. Kim J., Jiang H., Park S., Eltorai A.E., Stewart F.R., Yoon H., Basak J.M., Finn M.B., Holtzman D.M. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid-β amyloidosis. J.Neurosci. 2011, 31:18007-18012.
80. Kim J., Eltorai A.E., Jiang H., Liao F., Verghese P.B., Kim J., Stewart F.R., Basak J.M., Holtzman D.M. Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of Aβ amyloidosis. J.Exp. Med. 2012, 209:2149-2156.
81. Knauer M.F., Soreghan B., Burdick D., Kosmoski J., Glabe C.G. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. Proc. Natl. Acad. Sci. USA 1992, 89:7437-7441.
82. Koistinaho M., Lin S., Wu X., Esterman M., Koger D., Hanson J., Higgs R., Liu F., Malkani S., Bales K.R., Paul S.M. Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat. Med. 2004, 10:719-726.
83. Kok E., Haikonen S., Luoto T., Huhtala H., Goebeler S., Haapasalo H., Karhunen P.J. Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann. Neurol. 2009, 65:650-657.
84. Koldamova R., Fitz N.F., Lefterov I. The role of ATP-binding cassette transporter A1 in Alzheimer's disease and neurodegeneration. Biochim. Biophys. Acta 2010, 1801:824-830.
85. Kowal R.C., Herz J., Goldstein J.L., Esser V., Brown M.S. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA 1989, 86:5810-5814.
86. Kowal R.C., Herz J., Weisgraber K.H., Mahley R.W., Brown M.S., Goldstein J.L. Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protein. J.Biol. Chem. 1990, 265:10771-10779.
87. LaDu M.J., Falduto M.T., Manelli A.M., Reardon C.A., Getz G.S., Frail D.E. Isoform-specific binding of apolipoprotein E to beta-amyloid. J.Biol. Chem. 1994, 269:23403-23406.
88. LaDu M.J., Pederson T.M., Frail D.E., Reardon C.A., Getz G.S., Falduto M.T. Purification of apolipoprotein E attenuates isoform-specific binding to beta-amyloid. J.Biol. Chem. 1995, 270:9039-9042.
89. LaDu M.J., Gilligan S.M., Lukens J.R., Cabana V.G., Reardon C.A., Van Eldik L.J., Holtzman D.M. Nascent astrocyte particles differ from lipoproteins in CSF. J.Neurochem. 1998, 70:2070-2081.
90. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet. 2009, 41:1094-1099. European Alzheimer's Disease Initiative Investigators.
91. Laporte V., Lombard Y., Levy-Benezra R., Tranchant C., Poindron P., Warter J.M. Uptake of Abeta 1-40- and Abeta 1-42-coated yeast by microglial cells: a role for LRP. J.Leukoc. Biol. 2004, 76:451-461.
92. Laurén J., Gimbel D.A., Nygaard H.B., Gilbert J.W., Strittmatter S.M. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009, 457:1128-1132.
93. Leissring M.A., Farris W., Chang A.Y., Walsh D.M., Wu X., Sun X., Frosch M.P., Selkoe D.J. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 2003, 40:1087-1093.
94. Li J., Kanekiyo T., Shinohara M., Zhang Y., LaDu M.J., Xu H., Bu G. Differential regulation of amyloid-β endocytic trafficking and lysosomal degradation by apolipoprotein E isoforms. J.Biol. Chem. 2012, 287:44593-44601.
95. Liu Q., Zerbinatti C.V., Zhang J., Hoe H.S., Wang B., Cole S.L., Herz J., Muglia L., Bu G. Amyloid precursor protein regulates brain apolipoprotein E and cholesterol metabolism through lipoprotein receptor LRP1. Neuron 2007, 56:66-78.
96. Liu C.C., Kanekiyo T., Xu H., Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat. Rev. Neurol. 2013, 9:106-118.
97. Ma J., Yee A., Brewer H.B., Das S., Potter H. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments. Nature 1994, 372:92-94.
98. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
99. Mahley R.W., Rall S.C. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 2000, 1:507-537.
100. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J.Lipid Res. 2009, 50(Suppl):S183-S188.
101. Mandrekar S., Jiang Q., Lee C.Y., Koenigsknecht-Talboo J., Holtzman D.M., Landreth G.E. Microglia mediate the clearance of soluble Abeta through fluid phase macropinocytosis. J.Neurosci. 2009, 29:4252-4262.
102. Marques F., Sousa J.C., Sousa N., Palha J.A. Blood-brain-barriers in aging and in Alzheimer's disease. Mol. Neurodegener. 2013, 8:38.
103. Mawuenyega K.G., Sigurdson W., Ovod V., Munsell L., Kasten T., Morris J.C., Yarasheski K.E., Bateman R.J. Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 2010, 330:1774.
104. Mucke L., Selkoe D.J. Neurotoxicity of amyloid β-protein: synaptic and network dysfunction. Cold Spring Harb. Perspect. Med. 2012, 2:a006338.
105. Naiki H., Gejyo F., Nakakuki K. Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation invitro. Biochemistry 1997, 36:6243-6250.
106. Naj A.C., Jun G., Beecham G.W., Wang L.S., Vardarajan B.N., Buros J., Gallins P.J., Buxbaum J.D., Jarvik G.P., Crane P.K., et al. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat. Genet. 2011, 43:436-441.
107. Namba Y., Tomonaga M., Kawasaki H., Otomo E., Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res. 1991, 541:163-166.
108. Narita M., Holtzman D.M., Schwartz A.L., Bu G. Alpha2-macroglobulin complexes with and mediates the endocytosis of beta-amyloid peptide via cell surface low-density lipoprotein receptor-related protein. J.Neurochem. 1997, 69:1904-1911.
109. Nielsen H.M., Mulder S.D., Beliën J.A., Musters R.J., Eikelenboom P., Veerhuis R. Astrocytic A beta 1-42 uptake is determined by A beta-aggregation state and the presence of amyloid-associated proteins. Glia 2010, 58:1235-1246.
110. Nishitsuji K., Hosono T., Nakamura T., Bu G., Michikawa M. Apolipoprotein E regulates the integrity of tight junctions in an isoform-dependent manner in an invitro blood-brain barrier model. J.Biol. Chem. 2011, 286:17536-17542.
111. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., et al. Intraneuronal beta-amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J.Neurosci. 2006, 26:10129-10140.
112. Perálvarez-Marín A., Barth A., Gräslund A. Time-resolved infrared spectroscopy of pH-induced aggregation of the Alzheimer Abeta(1-28) peptide. J.Mol. Biol. 2008, 379:589-596.
113. Pérez E., Bourguet W., Gronemeyer H., de Lera A.R. Modulation of RXR function through ligand design. Biochim. Biophys. Acta 2012, 1821:57-69.
114. Petrlova J., Hong H.S., Bricarello D.A., Harishchandra G., Lorigan G.A., Jin L.W., Voss J.C. A differential association of Apolipoprotein E isoforms with the amyloid-β oligomer in solution. Proteins 2011, 79:402-416.
115. Pitas R.E., Boyles J.K., Lee S.H., Foss D., Mahley R.W. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 1987, 917:148-161.
116. Pitas R.E., Boyles J.K., Lee S.H., Hui D., Weisgraber K.H. Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain. J.Biol. Chem. 1987, 262:14352-14360.
117. Polvikoski T., Sulkava R., Haltia M., Kainulainen K., Vuorio A., Verkkoniemi A., Niinistö L., Halonen P., Kontula K. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N.Engl. J. Med. 1995, 333:1242-1247.
118. Rall S.C., Weisgraber K.H., Mahley R.W. Human apolipoprotein E. The complete amino acid sequence. J.Biol. Chem. 1982, 257:4171-4178.
119. Reiman E.M., Chen K., Liu X., Bandy D., Yu M., Lee W., Ayutyanont N., Keppler J., Reeder S.A., Langbaum J.B.S., et al. Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2009, 106:6820-6825.
120. Rensink A.A., de Waal R.M., Kremer B., Verbeek M.M. Pathogenesis of cerebral amyloid angiopathy. Brain Res. Brain Res. Rev. 2003, 43:207-223.
121. Revesz T., Ghiso J., Lashley T., Plant G., Rostagno A., Frangione B., Holton J.L. Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J.Neuropathol. Exp. Neurol. 2003, 62:885-898.
122. Richard E., Carrano A., Hoozemans J.J., van Horssen J., van Haastert E.S., Eurelings L.S., de Vries H.E., Thal D.R., Eikelenboom P., van Gool W.A., Rozemuller A.J. Characteristics of dyshoric capillary cerebral amyloid angiopathy. J.Neuropathol. Exp. Neurol. 2010, 69:1158-1167.
123. Riddell D.R., Zhou H., Comery T.A., Kouranova E., Lo C.F., Warwick H.K., Ring R.H., Kirksey Y., Aschmies S., Xu J., et al. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 2007, 34:621-628.
124. Rushworth J.V., Griffiths H.H., Watt N.T., Hooper N.M. Prion protein-mediated toxicity of amyloid-β oligomers requires lipid rafts and the transmembrane LRP1. J.Biol. Chem. 2013, 288:8935-8951.
125. Russo C., Angelini G., Dapino D., Piccini A., Piombo G., Schettini G., Chen S., Teller J.K., Zaccheo D., Gambetti P., Tabaton M. Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proc. Natl. Acad. Sci. USA 1998, 95:15598-15602.
126. Sadowski M., Pankiewicz J., Scholtzova H., Ripellino J.A., Li Y., Schmidt S.D., Mathews P.M., Fryer J.D., Holtzman D.M., Sigurdsson E.M., Wisniewski T. A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation invitro and reduces beta-amyloid plaques in transgenic mice. Am. J. Pathol. 2004, 165:937-948.
127. Saido T., Leissring M.A. Proteolytic degradation of amyloid β-protein. Cold Spring Harb. Perspect. Med. 2012, 2:a006379.
128. Saito H., Dhanasekaran P., Nguyen D., Baldwin F., Weisgraber K.H., Wehrli S., Phillips M.C., Lund-Katz S. Characterization of the heparin binding sites in human apolipoprotein E. J.Biol. Chem. 2003, 278:14782-14787.
129. Schneider W.J., Kovanen P.T., Brown M.S., Goldstein J.L., Utermann G., Weber W., Havel R.J., Kotite L., Kane J.P., Innerarity T.L., Mahley R.W. Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows. J.Clin. Invest. 1981, 68:1075-1085.
130. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J.Clin. Invest. 2000, 106:1489-1499.
131. Shinohara M., Sato N., Kurinami H., Takeuchi D., Takeda S., Shimamura M., Yamashita T., Uchiyama Y., Rakugi H., Morishita R. Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. J.Biol. Chem. 2010, 285:22091-22102.
132. Shinohara M., Petersen R.C., Dickson D.W., Bu G. Brain regional correlation of amyloid-β with synapses and apolipoprotein E in non-demented individuals: potential mechanisms underlying regional vulnerability to amyloid-β accumulation. Acta Neuropathol. 2013, 125:535-547.
133. Sivashanmugam A., Wang J. A unified scheme for initiation and conformational adaptation of human apolipoprotein E N-terminal domain upon lipoprotein binding and for receptor binding activity. J.Biol. Chem. 2009, 284:14657-14666.
134. Strittmatter W.J., Weisgraber K.H., Huang D.Y., Dong L.M., Salvesen G.S., Pericak-Vance M., Schmechel D., Saunders A.M., Goldgaber D., Roses A.D. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90:8098-8102.
135. Tai L.M., Bilousova T., Jungbauer L., Roeske S.K., Youmans K.L., Yu C., Poon W.W., Cornwell L.B., Miller C.A., Vinters H.V., et al. Levels of soluble apolipoprotein E/amyloid-β (Aβ) complex are reduced and oligomeric Aβ increased with APOE4 and Alzheimer disease in a transgenic mouse model and human samples. J.Biol. Chem. 2013, 288:5914-5926.
136. Tamamizu-Kato S., Cohen J.K., Drake C.B., Kosaraju M.G., Drury J., Narayanaswami V. Interaction with amyloid beta peptide compromises the lipid binding function of apolipoprotein E. Biochemistry 2008, 47:5225-5234.
137. Terwel D., Steffensen K.R., Verghese P.B., Kummer M.P., Gustafsson J.A., Holtzman D.M., Heneka M.T. Critical role of astroglial apolipoprotein E and liver X receptor-α expression for microglial Aβ phagocytosis. J.Neurosci. 2011, 31:7049-7059.
138. Thal D.R., Ghebremedhin E., Rüb U., Yamaguchi H., Del Tredici K., Braak H. Two types of sporadic cerebral amyloid angiopathy. J.Neuropathol. Exp. Neurol. 2002, 61:282-293.
139. Thies W., Bleiler L. 2013 Alzheimer's disease facts and figures. Alzheimers Dement. 2013, 9:208-245. Alzheimer's Association.
140. Tokuda T., Calero M., Matsubara E., Vidal R., Kumar A., Permanne B., Zlokovic B., Smith J.D., Ladu M.J., Rostagno A., et al. Lipidation of apolipoprotein E influences its isoform-specific interaction with Alzheimer's amyloid beta peptides. Biochem. J. 2000, 348:359-365.
141. Utermann G., Hees M., Steinmetz A. Polymorphism of apolipoprotein E and occurrence of dysbetalipoproteinaemia in man. Nature 1977, 269:604-607.
142. van Horssen J., Wesseling P., van den Heuvel L.P., de Waal R.M., Verbeek M.M. Heparan sulphate proteoglycans in Alzheimer's disease and amyloid-related disorders. Lancet Neurol. 2003, 2:482-492.
143. Verghese P.B., Castellano J.M., Garai K., Wang Y., Jiang H., Shah A., Bu G., Frieden C., Holtzman D.M. ApoE influences amyloid-β (Aβ) clearance despite minimal apoE/Aβ association in physiological conditions. Proc. Natl. Acad. Sci. USA 2013, 110:E1807-E1816.
144. Vincent B., Smith J.D. Astrocytes down-regulate neuronal beta-amyloid precursor protein expression and modify its processing in an apolipoprotein E isoform-specific manner. Eur. J. Neurosci. 2001, 14:256-266.
145. Wahrle S.E., Jiang H., Parsadanian M., Hartman R.E., Bales K.R., Paul S.M., Holtzman D.M. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J.Biol. Chem. 2005, 280:43236-43242.
146. Wahrle S.E., Shah A.R., Fagan A.M., Smemo S., Kauwe J.S., Grupe A., Hinrichs A., Mayo K., Jiang H., Thal L.J., et al. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol. Neurodegener. 2007, 2:7.
147. Wahrle S.E., Jiang H., Parsadanian M., Kim J., Li A., Knoten A., Jain S., Hirsch-Reinshagen V., Wellington C.L., Bales K.R., et al. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J.Clin. Invest. 2008, 118:671-682.
148. Wang H., Ren C.H., Gunawardana C.G., Schmitt-Ulms G. Overcoming barriers and thresholds - signaling of oligomeric Aβ through the prion protein to Fyn. Mol. Neurodegener. 2013, 8:24.
149. Weisgraber K.H., Rall S.C., Mahley R.W. Human E apoprotein heterogeneity. Cysteine-arginine interchanges in the amino acid sequence of the apo-E isoforms. J.Biol. Chem. 1981, 256:9077-9083.
150. Wernette-Hammond M.E., Lauer S.J., Corsini A., Walker D., Taylor J.M., Rall S.C. Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194. J.Biol. Chem. 1989, 264:9094-9101.
151. Wilsie L.C., Orlando R.A. The low density lipoprotein receptor-related protein complexes with cell surface heparan sulfate proteoglycans to regulate proteoglycan-mediated lipoprotein catabolism. J.Biol. Chem. 2003, 278:15758-15764.
152. Wilson C., Wardell M.R., Weisgraber K.H., Mahley R.W., Agard D.A. Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E. Science 1991, 252:1817-1822.
153. Winkler K., Scharnagl H., Tisljar U., Hoschützky H., Friedrich I., Hoffmann M.M., Hüttinger M., Wieland H., März W. Competition of Abeta amyloid peptide and apolipoprotein E for receptor-mediated endocytosis. J.Lipid Res. 1999, 40:447-455.
154. Wisniewski T., Golabek A., Matsubara E., Ghiso J., Frangione B. Apolipoprotein E: binding to soluble Alzheimer's beta-amyloid. Biochem. Biophys. Res. Commun. 1993, 192:359-365.
155. Wood S.J., Chan W., Wetzel R. An ApoE-Abeta inhibition complex in Abeta fibril extension. Chem. Biol. 1996, 3:949-956.
156. Wood S.J., Chan W., Wetzel R. Seeding of A beta fibril formation is inhibited by all three isotypes of apolipoprotein E. Biochemistry 1996, 35:12623-12628.
157. Xu Q., Brecht W.J., Weisgraber K.H., Mahley R.W., Huang Y. Apolipoprotein E4 domain interaction occurs in living neuronal cells as determined by fluorescence resonance energy transfer. J.Biol. Chem. 2004, 279:25511-25516.
158. Xu Q., Bernardo A., Walker D., Kanegawa T., Mahley R.W., Huang Y. Profile and regulation of apolipoprotein E (ApoE) expression in the CNS in mice with targeting of green fluorescent protein gene to the ApoE locus. J.Neurosci. 2006, 26:4985-4994.
159. Yamada K., Hashimoto T., Yabuki C., Nagae Y., Tachikawa M., Strickland D.K., Liu Q., Bu G., Basak J.M., Holtzman D.M., et al. The low density lipoprotein receptor-related protein 1 mediates uptake of amyloid beta peptides in an invitro model of the blood-brain barrier cells. J.Biol. Chem. 2008, 283:34554-34562.
160. Youmans K.L., Tai L.M., Nwabuisi-Heath E., Jungbauer L., Kanekiyo T., Gan M., Kim J., Eimer W.A., Estus S., Rebeck G.W., et al. APOE4-specific changes in Aβ accumulation in a new transgenic mouse model of Alzheimer disease. J.Biol. Chem. 2012, 287:41774-41786.
161. Zannis V.I., Breslow J.L. Human very low density lipoprotein apolipoprotein E isoprotein polymorphism is explained by genetic variation and posttranslational modification. Biochemistry 1981, 20:1033-1041.
162. Zerbinatti C.V., Wahrle S.E., Kim H., Cam J.A., Bales K., Paul S.M., Holtzman D.M., Bu G. Apolipoprotein E and low density lipoprotein receptor-related protein facilitate intraneuronal Abeta42 accumulation in amyloid model mice. J.Biol. Chem. 2006, 281:36180-36186.
163. Zhu Y., Nwabuisi-Heath E., Dumanis S.B., Tai L.M., Yu C., Rebeck G.W., LaDu M.J. APOE genotype alters glial activation and loss of synaptic markers in mice. Glia 2012, 60:559-569.